Quarterly report · Q1
2533.TEDINET S100TDK1
Period2024-01-01 → 2024-03-31
Filed2024-05-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.8bn | 2024-01-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥84.9bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥20.8bn | 2023-01-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥624m | 2024-01-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥876m | 2023-01-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥673m | 2024-01-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.7bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥882m | 2023-01-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥670m | 2024-01-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥882m | 2023-01-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥498m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥797m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥498m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥788m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥55.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥55.4bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥53.8bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥32.6bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥33.2bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥22.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥22.2bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.1bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥987m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥828m | at 2023-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥8.57 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.3 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.7 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.6% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.0% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-03-31 | ¥22m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-03-31 | ¥19m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-03-31 | ¥3m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-03-31 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-03-31 | −¥3m |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥1.1bn |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥1.1bn |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥172m |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥17.4bn |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥17.4bn |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥1m |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥295m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥283m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥283m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥152m |
| —segment total | revenue | 2024-01-01 → 2024-03-31 | ¥18.8bn |
| —segment total | revenue external | 2024-01-01 → 2024-03-31 | ¥18.8bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥1m |
| —segment total | segment profit | 2024-01-01 → 2024-03-31 | ¥620m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-03-31 | ¥20m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-03-31 | ¥20m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-03-31 | ¥0 |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥0 |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥921m |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥921m |
| jpcrp040300-q1r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥265m |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥18.3bn |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥18.3bn |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥0 |
| jpcrp040300-q1r_E00397-000Liquorreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥485m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥252m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥252m |
| jpcrp040300-q1r_E00397-000Real Estatereportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥130m |
| jpcrp040300-q1r_E00397-000Starch For Processingreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E00397-000Starch For Processingreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E00397-000Starch For Processingreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥6m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥20.8bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥20.8bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥0 |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | ¥875m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 400
| Item | Context | Value | Unit |
|---|---|---|---|
| Foreign exchange gains noi | Prior1YTDDuration | 11000000 | JPY |
| Foreign exchange gains noi | CurrentYTDDuration | 16000000 | JPY |
| Miscellaneous income noi | Prior1YTDDuration | 9000000 | JPY |
| Miscellaneous income noi | CurrentYTDDuration | 9000000 | JPY |
| Non operating income | Prior1YTDDuration | 44000000 | JPY |
| Non operating income | CurrentYTDDuration | 83000000 | JPY |
| Interest expenses noe | Prior1YTDDuration | 24000000 | JPY |
| Interest expenses noe | CurrentYTDDuration | 22000000 | JPY |
| Cost during the suspension of plant operation noe | Prior1YTDDuration | 6000000 | JPY |
| Cost during the suspension of plant operation noe | CurrentYTDDuration | 6000000 | JPY |
| Miscellaneous loss noe | Prior1YTDDuration | 7000000 | JPY |
| Miscellaneous loss noe | CurrentYTDDuration | 5000000 | JPY |
| Non operating expenses | Prior1YTDDuration | 37000000 | JPY |
| Non operating expenses | CurrentYTDDuration | 34000000 | JPY |
| Ordinary income | Prior1YTDDuration | 882000000 | JPY |
| Ordinary income | CurrentYTDDuration | 673000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | Prior1YTDDuration | 0 | JPY |
| Loss on sales and retirement of noncurrent assets el | CurrentYTDDuration | 1000000 | JPY |
| Other el | Prior1YTDDuration | － | JPY |
| Other el | CurrentYTDDuration | 0 | JPY |
| Extraordinary loss | Prior1YTDDuration | 0 | JPY |
| Extraordinary loss | CurrentYTDDuration | 2000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 882000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 670000000 | JPY |
| Income taxes | Prior1YTDDuration | 94000000 | JPY |
| Income taxes | CurrentYTDDuration | 172000000 | JPY |
| Profit loss | Prior1YTDDuration | 788000000 | JPY |
| Profit loss | CurrentYTDDuration | 498000000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | -9000000 | JPY |
| Profit loss attributable to non controlling interests | CurrentYTDDuration | -0 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 797000000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 498000000 | JPY |
| Profit loss | Prior1YTDDuration | 788000000 | JPY |
| Profit loss | CurrentYTDDuration | 498000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | -6000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 309000000 | JPY |
| Deferred gains or losses on hedges net of tax oci | Prior1YTDDuration | 39000000 | JPY |
| Deferred gains or losses on hedges net of tax oci | CurrentYTDDuration | 169000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | 1000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | 0 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | Prior1YTDDuration | － | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | CurrentYTDDuration | 3000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 34000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 483000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 822000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 981000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 826000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 982000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | -4000000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | -0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |